arches: os by high or low disease volume and progression to mhspc or de novo mhspc
Published 2 years ago • 237 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
1:37
arches: os in mhspc who recieved prior adt and reached low psa further treated with enzalutamide
-
5:11
enzalutamide adt in men with de novo mhspc: the arches trial
-
1:30
final os analysis from arches
-
3:03
arches post-hoc analyses: efficacy of enza adt in mhspc by pattern of metastatic spread
-
2:37
arches trial: enzalutamide plus adt for mhspc
-
7:49
prostate cancer recurrence in pelvic lymph nodes (high-indigo stage) | prostate cancer staging guide
-
16:43
high-risk prostate cancer
-
22:56
bone & ct scans vs next-generation imaging for metastatic hormone sensitive prostate cancer
-
3:18
arches: radiographic progression in the absence of psa progression in patients with mhspc
-
6:05
enzamet trial
-
6:00
arches trial
-
1:36
genomic characterization of patients with de-novo high-volume mcspc compared to those without
-
15:57
mhspc: chemo-hormonal therapy and treatment intensification
-
3:43
arches trial: androgen deprivation therapy with enzalutamide or placebo in mhspc
-
2:25
subgroups of metastatic hormone-sensitive prostate cancer (mhspc)
-
3:37
prevalence of ddr alterations in patients with mhspc enrolled in arches
-
2:18
arches: enzalutamide plus adt in mhspc subgroups
-
6:02
update on the arches trial: new indication for enzalutamide in mhspc
-
3:57
update on arches trial: implications for prostate cancer treatment
-
2:04
update on overall survival in arches trial
-
20:07
management of mhspc
-
1:10
preside: investigating continued treatment with enzalutamide in pc following disease progression